tumor-infiltrating lymphocytes

[Proceedings of the National Academy of Sciences of the United States of America] Leveraging the use of mass cytometry combined with multiplex major histocompatibility complex class I tetramer staining, researchers screened and identified tumor neoantigen–specific CD8+ T cells in the Lewis Lung carcinoma tumor model.

[Nature] Scientists identified mutation-associated neoantigens (MANA)-specific T cell clones using the MANA functional expansion of specific T cells assay3 in neoadjuvant anti-PD-1-treated non-small cell lung cancers.

[Scientific Reports] Considering the effect of KRAS mutations on tumor microenvironment, investigators analyzed the prognostic significance of KRAS mutation types after adjusting for the tumor-infiltrating lymphocytes and tumor-stromal percentage statuses.

[Biochimica et Biophysica Acta-Reviews On Cancer] Investigators review the current progress targeting different immune checkpoints in several-lines treatment for TNBC, including programmed death-1/programmed death ligand-1 inhibitors, cytotoxic T-lymphocyte associated antigen-4 inhibitor, and other novel immunotherapeutic approaches.

[Communications Biology] Researchers showed that a combination immunotherapy platform utilizing low dose chemotherapy combined with oncolytic virotherapy increased tumor-infiltrating lymphocytes, in otherwise immune-bare tumors, allowing 60% of mice to achieve durable tumor regression when treated with immune checkpoint blockade.

[Oncogene] Despite its well-documented inhibitory effects, higher PD-1 expression in tumor-infiltrating lymphocytes was significantly associated with longer survival in triple-negative breast cancer patients.